CPHI Milan 2026 and NTC’s 10th anniversary: celebrating a decade of innovation and looking ahead

CPHI Milan 2026 and NTC’s 10th anniversary: celebrating a decade of innovation and looking ahead

  • 21 Oct, 2026

Milan, October 2026 - This year’s CPHI Milan 2026 was an opportunity for NTC to connect with customers, partners, and stakeholders from across the global pharmaceutical industry, and also a perfect occasion to celebrate an important milestone: 10 years of growth, innovation, and international expansion, while setting ambitious goals for the future.

Throughout the CPHI exhibition, the NTC team welcomed partners and collaborators from around the world, strengthened existing relationships, and explored new growth opportunities.

Today, NTC operates in more than 100 countries through a network of over 300 distributors and partners, reinforcing its position as one of Europe’s leading ophthalmology-focused pharmaceutical companies.

Over the past decade, ophthalmology has remained at the core of NTC’s mission. The company has built a portfolio addressing a broad range of therapeutic needs, from ocular surface diseases and anti-infective treatments to innovative solutions in glaucoma and retinal care. Alongside ophthalmology, NTC continues to expand strategic partnerships in gynaecology, gastro-metabolism, and dermatology.

The celebrations continued October 7th at NTC’s headquarters in Milan, where employees, customers, suppliers, and business partners gathered to mark the company’s tenth anniversary.

The event recognized the people and collaborations that have contributed to NTC’s success story.

Guests had the opportunity to revisit NTC’s journey from a young Italian pharmaceutical company to a recognized international player and the first Italian company to successfully launch ophthalmic products on a global scale.

As NTC enters its second decade, innovation remains a key priority.

“Ten years ago, we set out to build a company capable of delivering meaningful innovation in ophthalmology. Today, our global presence and expanding portfolio demonstrate what can be achieved through vision, scientific excellence, and strong partnerships. While we celebrate this important milestone, we look ahead with the same ambition and entrepreneurial spirit that have driven us from the beginning,” said Riccardo Carbucicchio, CEO of NTC.

Participation in CPHI Milan 2026 and the celebration of NTC’s 10th anniversary represent an important achievement and the beginning of a new chapter. With the same determination that has characterized its first decade, NTC will continue investing in research, international growth, and innovative healthcare solutions aimed at improving patients’ quality of life around the world.